Michele Mayo
0009-0005-0359-7900
Publication & Citation Trends
Publications
0 total
Abstract LB118: Mechanisms underlying synergistic activity in MYD88MTDLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrate
Cited by 5
Semantic Scholar
603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy OA
Cited by 0
Semantic Scholar
Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma OA
Cited by 0
Semantic Scholar
588 Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa OA
Cited by 1
Semantic Scholar
Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models OA
Cited by 4
Semantic Scholar
Abstract 5222: Degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenograftsin vivo
Cited by 0
Semantic Scholar
Abstract LB-088: A STAT3 selective targeted protein degrader decreases the immunesuppressive tumor microenvironment and drives antitumor activity in preclinical models
Cited by 0
Semantic Scholar
Discovery of a series of 5-AzaQuinazolines as orally efficacious IRAK4 inhibitors targeting MyD88L265P mutant Diffuse Large B Cell Lymphoma.
Cited by 15
Semantic Scholar
Research Topics
HER2/EGFR in Cancer Research
(27)
Cancer-related Molecular Pathways
(21)
Monoclonal and Polyclonal Antibodies Research
(21)
Synthesis and Biological Evaluation
(13)
Protein Degradation and Inhibitors
(8)
Affiliations
AstraZeneca (United Kingdom)
U.S. Army Research Institute of Environmental Medicine
Pennsylvania State University
University of Connecticut
Czech Agrifood Research Center